CN102552156B - Nimodipine freeze-dried solid lipid nanoparticle and preparation method thereof - Google Patents
Nimodipine freeze-dried solid lipid nanoparticle and preparation method thereof Download PDFInfo
- Publication number
- CN102552156B CN102552156B CN201210083247.5A CN201210083247A CN102552156B CN 102552156 B CN102552156 B CN 102552156B CN 201210083247 A CN201210083247 A CN 201210083247A CN 102552156 B CN102552156 B CN 102552156B
- Authority
- CN
- China
- Prior art keywords
- lipid nanoparticle
- solid lipid
- freeze
- nimodipine
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention discloses nimodipine freeze-dried solid lipid nanoparticles, which are prepared by mixing a solid lipid nanoparticle solution with a freeze-drying protective agent and freeze-drying, wherein 20g to 40g of the freeze-drying protective agent is added into every 100mL of the solid lipid nanoparticle solution; the 100mL solid lipid nanoparticle solution is prepared from the following raw materials: 2-20 mg of nimodipine, 0.5-4 g of phospholipid, 0-0.2 g of cholesterol sodium sulfate, 0.02-0.4 g of propylene glycol block polyether and the balance of phosphate buffer solution; the freeze-drying protective agent is one or more of sucrose, glucose, trehalose, maltose and mannitol. The nimodipine freeze-dried solid lipid nanoparticle provided by the invention has the drug loading capacity of 0.2mg/mL, is good in state after re-dissolution, has the characteristics of high efficiency, low toxicity, stability and the like, can improve the compliance of patients, and is suitable for clinical application, and the physicochemical property of the nimodipine freeze-dried solid lipid nanoparticle meets the requirements of intravenous injection.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Nimodipine freeze-drying solid lipid nanoparticle and preparation method thereof.
Background technology
Nimodipine (Nimodipine NMD) is second filial generation dihydropyridine calcium ion antagonist, and the 1980s is synthetic by Bayer A.G, and its structural formula is as follows:
Nimodipine can selectively acting in calcium channel, specifically with the reversible combination of relevant receptor, regulate calcium ion concentration in the vascular smooth muscle, cause smooth muscle loosening, reverse vasospasm, improve blood supply.Because nimodipine is fat-soluble medicine, can pass through blood brain barrier, therefore can protect brain cell, improve it to the toleration of anoxia.The clinical ischemic cerebrovascular that is usually used in, diseases such as the cerebral vasospasm that subarachnoid hemorrhage causes, apoplexy and migraine also can be improved memory etc.
The nimodipine better tolerance, side effect is little, but has serious liver first-pass effect, and oral administration biaavailability is low, and therefore widely used clinically is its injection.The nimodipine poorly water-soluble contains the ethanol of high concentration in the injection, during use with glucose or normal saline dilution, separate out precipitation sometimes, therefore and ethanol has zest to blood vessel, and efficient, the low toxicity of exploitation and stable nimodipine novel form have great importance.
Solid lipid nanoparticle is structurally similar with liposome, and liposome means drug encapsulation in the lipoids bilayer and the micro-bubbles utricule that forms.It structurally says, the interior water in the middle of having can water soluble medicament-entrapping, belongs to hollow-core construction.And solid lipid nanoparticle is to be carrier with solid natural or synthetic lipoid, with the medicine parcel or clamp the solid micelle drug-supplying system of making in lipoid nuclear, says that structurally it belongs to solid construction, and easier bag carries fat-soluble medicine.
The prepared liposome of the disclosed Nimodipime nanometer liposome preparation of CN1418626A technology, although safety preferably and biocompatibility are arranged and stride film, its stability is not fine, and is bigger than normal with the particle diameter of the liposome of this method preparation yet.CN1554340A provides a kind of Nimodipime nanometer liposome and precursor freeze-dried composition thereof with good brain targeting, and its mean diameter is below 100nm, but the change of size situation after not providing freeze-dried composition and redissolving and the data of stability.And the quality evaluation after the lyophilizing is the important measurement index of lyophilized formulations.CN1903173A discloses a kind of its preparation method of Nimodipine nanometer granule, its drug loading and stability still can, but particle diameter is bigger, the mean diameter after the redissolution is below 0.3 μ m, bigger particle diameter will be unfavorable for that the brain targeting also is unfavorable for intravenously administrable.
Summary of the invention
Technical problem to be solved by this invention is at above-mentioned the deficiencies in the prior art, and a kind of Nimodipine freeze-drying solid lipid nanoparticle of stable Gong clinical practice is provided.This lyophilized solid lipid nanoparticle is in good condition after redissolving, and its physicochemical property meets the used for intravenous injection requirement, has improved patient's compliance simultaneously, is suitable for clinical practice.
For solving the problems of the technologies described above, the technical solution used in the present invention is: a kind of Nimodipine freeze-drying solid lipid nanoparticle, it is characterized in that, mix the back lyophilizing with freeze drying protectant by solid lipid nanoparticle solution and make, add 20g～40g freeze drying protectant in every 100mL solid lipid nanoparticle solution; The described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 2mg～20mg, and phosphatidase 10 .5g～4g, cholesterol sodium sulfate salt 0g～0.2g, propylene glycol block polyether 0.02g～0.4g, surplus is phosphate buffered solution; Described freeze drying protectant is one or more in sucrose, glucose, trehalose, maltose and the mannitol.
Above-mentioned a kind of Nimodipine freeze-drying solid lipid nanoparticle, the described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 20mg, phosphatidase 12 g, cholesterol sodium sulfate salt 0.1g, propylene glycol block polyether 0.2g, surplus is phosphate buffered solution.
Above-mentioned a kind of Nimodipine freeze-drying solid lipid nanoparticle, described phospholipid are injection stage Ovum Gallus domesticus Flavus lecithin PL-100M; Described propylene glycol block polyether is propylene glycol block polyether F-68.
Above-mentioned a kind of Nimodipine freeze-drying solid lipid nanoparticle, described freeze drying protectant is mannitol and trehalose, the mass ratio of mannitol and trehalose is 1: 2.
Above-mentioned a kind of Nimodipine freeze-drying solid lipid nanoparticle, mannitol and the trehalose of adding 30g in every 100mL solid lipid nanoparticle solution.
In addition, the present invention also provides the preparation method of above-mentioned Nimodipine freeze-drying solid lipid nanoparticle, it is characterized in that, this method may further comprise the steps:
Step 1, take by weighing nimodipine, phospholipid and cholesterol sodium sulfate salt respectively, nimodipine, phospholipid and the cholesterol sodium sulfate salt that takes by weighing mixed back heating for dissolving under magnetic agitation, obtain the homogeneous oil phase;
Above-mentioned method, the temperature that heats described in the step 1 are 60 ℃.
Above-mentioned method, stir speed (S.S.) described in the step 3 are 500rpm.
Above-mentioned method, ultrasonic power is 750W described in the step 4, ultrasonic time is 10min.
Above-mentioned method, described ultrasonic employing is ultrasonic power at interval, is specially: the every processing of ultrasound wave 3s, intermittently 1s.
The present invention is model drug with the nimodipine, uses emulsifying-ultrasonic method successfully to prepare the Nimodipine solid lipid nanoparticle.By to the optimization of freeze drying process with to the screening of freeze drying protectant prescription, developing of success is efficient, low toxicity and stable Nimodipine freeze-drying solid lipid nanoparticle.
The present invention compared with prior art has the following advantages:
1, Nimodipine freeze-drying solid lipid nanoparticle of the present invention, its drug loading can reach 0.2mg/mL, and is in good condition after redissolving, its physicochemical property meets the used for intravenous injection requirement, have efficient, low toxicity, characteristics such as stable, can improve patient's compliance, be suitable for clinical practice.
2, the present invention is through deep research, select for use cholesterol sodium sulfate salt (SCS) as stabilizing agent, SCS is derived behind Sulfation by cholesterol, it has emulsification as a kind of composition of new membrane stability material participation solid lipid nanoparticle again when playing adjusting membrane fluidity function.Along with the increase of SCS ratio, the clarity of solid lipid nanoparticle increases, and particle diameter reduces and distributes wide, and the absolute value of zeta current potential becomes greatly simultaneously; Compare with cholesterol, the adding of SCS can be so that the solid lipid nanoparticle particle diameter reduces, under the identical situation of addition, the solid lipid nanoparticle particle diameter that makes with SCS is than little many of the lipid nanoparticle particle diameter that makes with cholesterol, and it is big that the absolute value of zeta current potential is wanted, and the size of zeta current potential affects stability of formulation in a way.
3, the deep research of process among the present invention selects for use the nonionic emulsifier propylene glycol block polyether as emulsifying agent, can improve the stability of envelop rate and the solid lipid nanoparticle of medicine in the dissolubility that increases liposoluble constituent; Simultaneously, select for use existing lipophilic group that the injection stage Ovum Gallus domesticus Flavus lecithin PL-100M of hydrophilic group is arranged again, in preparation process, easily form vesicle.
4, adopt the Nimodipine solid lipid nanoparticle of method preparation of the present invention in freeze-drying process, to have good mouldability; can be by intact protection; form and the particle diameter of solid lipid nanoparticle has only minor variations before the lyophilizing and after the rehydration; mean diameter is about 100nm; it is stable that every physicochemical property keeps before and after lyophilizing, meets the intravenous administration requirement.
5, the result of Nimodipine freeze-drying solid lipid nanoparticle long-time stability investigation of the present invention shows: placed 3 months under 25 ± 2 ℃ condition, its outward appearance, residual moisture, pH value, particle diameter and envelop rate all do not have significant change, still meet the requirement of intravenous administration.
Below in conjunction with drawings and Examples, technical scheme of the present invention is described in further detail.
Description of drawings
Fig. 1 is the preceding transmission electron microscope photo of Nimodipine freeze-drying solid lipid nanoparticle lyophilizing of the embodiment of the invention 1 preparation.
Fig. 2 is the transmission electron microscope photo after the Nimodipine freeze-drying solid lipid nanoparticle of the embodiment of the invention 1 preparation redissolves.
Fig. 3 is the drug release curve in pH 7.4 phosphate buffers that contain 30% ethanol before and after the Nimodipine freeze-drying solid lipid nanoparticle lyophilizing of the embodiment of the invention 1 preparation.
Fig. 4 is single dose vena femoralis injection Nimodipine freeze-drying solid lipid nanoparticle of the present invention and the average blood drug level of solution-type nimotop vial and the curve of time.
The specific embodiment
Embodiment 1
The Nimodipine freeze-drying solid lipid nanoparticle of present embodiment mixes the back lyophilizing by solid lipid nanoparticle solution and makes with freeze drying protectant; The described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 20mg, and phosphatidase 12 g, cholesterol sodium sulfate salt 0.1g, propylene glycol block polyether 0.2g, surplus is phosphate buffered solution; Described freeze drying protectant is mannitol and trehalose, and wherein the consumption of mannitol is every 100mL solid lipid nanoparticle solution 10g mannitol, and the consumption of trehalose is every 100mL solid lipid nanoparticle solution 20g trehalose; Described phospholipid is injection stage Ovum Gallus domesticus Flavus lecithin PL-100M; Described propylene glycol block polyether is propylene glycol block polyether F-68.
The preparation method of the Nimodipine freeze-drying solid lipid nanoparticle of present embodiment may further comprise the steps:
Step 1, take by weighing 20mg nimodipine, 2g injection stage Ovum Gallus domesticus Flavus lecithin PL-100M and 0.1g cholesterol sodium sulfate salt respectively, nimodipine, injection stage Ovum Gallus domesticus Flavus lecithin PL-100M and the cholesterol sodium sulfate salt that takes by weighing mixed the back under stirring condition, be heated to 60 ℃ of dissolvings, obtain the homogeneous oil phase;
Present embodiment is identical with embodiment 1; wherein difference is: described freeze drying protectant is a kind of in sucrose, glucose, trehalose, maltose and the mannitol or more than three kinds; perhaps being two kinds in sucrose, glucose, maltose and the mannitol, perhaps is the mixture of a kind of and trehalose in sucrose, glucose and the maltose.
The Nimodipine freeze-drying solid lipid nanoparticle of present embodiment mixes the back lyophilizing by solid lipid nanoparticle solution and makes with freeze drying protectant; The described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 10mg, and phosphatidase 11 g, cholesterol sodium sulfate salt 0.05g, propylene glycol block polyether 0.1g, surplus is phosphate buffered solution; Described freeze drying protectant is mannitol and trehalose, and wherein the consumption of mannitol is every 100mL solid lipid nanoparticle solution 10g mannitol, and the consumption of trehalose is every 100mL solid lipid nanoparticle solution 20g trehalose; Described phospholipid is injection stage Ovum Gallus domesticus Flavus lecithin PL-100M; Described propylene glycol block polyether is propylene glycol block polyether F-68.
The preparation method of the Nimodipine freeze-drying solid lipid nanoparticle of present embodiment may further comprise the steps:
Step 1, take by weighing 10mg nimodipine, 1g injection stage Ovum Gallus domesticus Flavus lecithin PL-100M and 0.05g cholesterol sodium sulfate salt respectively, nimodipine, injection stage Ovum Gallus domesticus Flavus lecithin PL-100M and the cholesterol sodium sulfate salt that takes by weighing mixed the back under stirring condition, be heated to 60 ℃ of dissolvings, obtain the homogeneous oil phase;
Present embodiment is identical with embodiment 3; wherein difference is: described freeze drying protectant is a kind of in sucrose, glucose, trehalose, maltose and the mannitol or more than three kinds; perhaps being two kinds in sucrose, glucose, maltose and the mannitol, perhaps is the mixture of a kind of and trehalose in sucrose, glucose and the maltose.
The Nimodipine freeze-drying solid lipid nanoparticle of present embodiment mixes the back lyophilizing by solid lipid nanoparticle solution and makes with freeze drying protectant; The described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 2mg, and phosphatidase 10 .5g, propylene glycol block polyether 0.02g, surplus is phosphate buffered solution; Described freeze drying protectant is sucrose, and the consumption of sucrose is every 100mL solid lipid nanoparticle solution 20g sucrose; Described phospholipid is injection stage Ovum Gallus domesticus Flavus lecithin PL-100M; Described propylene glycol block polyether is propylene glycol block polyether F-68.
The preparation method of the Nimodipine freeze-drying solid lipid nanoparticle of present embodiment may further comprise the steps:
Step 1, take by weighing 2mg nimodipine and 0.5g injection stage Ovum Gallus domesticus Flavus lecithin PL-100M respectively, the nimodipine that takes by weighing and injection stage Ovum Gallus domesticus Flavus lecithin PL-100M are mixed the back under stirring condition, be heated to 60 ℃ of dissolvings, obtain the homogeneous oil phase;
Present embodiment is identical with embodiment 5, and wherein difference is: described freeze drying protectant is glucose, trehalose, maltose or mannitol, perhaps is at least two kinds in sucrose, glucose, trehalose, maltose and the mannitol.
Embodiment 7
The Nimodipine freeze-drying solid lipid nanoparticle of present embodiment mixes the back lyophilizing by solid lipid nanoparticle solution and makes with freeze drying protectant; The described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 20mg, and phosphatidase 14 g, cholesterol sodium sulfate salt 0.2g, propylene glycol block polyether 0.4g, surplus is phosphate buffered solution; Described freeze drying protectant be sucrose, glucose, trehalose, maltose and mannitol by etc. mass ratio mix, the freeze drying protectant total amount is every 100mL solid lipid nanoparticle solution 40g freeze drying protectant; Described phospholipid is injection stage Ovum Gallus domesticus Flavus lecithin PL-100M; Described propylene glycol block polyether is propylene glycol block polyether F-68.
The preparation method of the Nimodipine freeze-drying solid lipid nanoparticle of present embodiment may further comprise the steps:
Step 1, take by weighing 20mg nimodipine, 4g injection stage Ovum Gallus domesticus Flavus lecithin PL-100M and 0.2g cholesterol sodium sulfate salt respectively, nimodipine, injection stage Ovum Gallus domesticus Flavus lecithin PL-100M and the cholesterol sodium sulfate salt that takes by weighing mixed the back under stirring condition, be heated to 60 ℃ of dissolvings, obtain the homogeneous oil phase;
Embodiment 8
Present embodiment is identical with embodiment 7, and wherein difference is: described freeze drying protectant is four kinds at the most in sucrose, glucose, trehalose, maltose and the mannitol.
Nimodipine freeze-drying solid lipid nanoparticle of the present invention is carried out following detection test:
One, the outward appearance of Nimodipine freeze-drying solid lipid nanoparticle detects
Nimodipine freeze-drying solid lipid nanoparticle of the present invention is carried out perusal, be spongy agglomerate, visible obvious blue opalescence, naked eyes and microscopically are observed does not all have insoluble composition or block aggregate.Nimodipine freeze-drying solid lipid nanoparticle outward appearance is not subsided, not shrinkage, color even, hole densification, any surface finish, and volume keeps the volume before the lyophilizing.Outward appearance was translucent milky after the Nimodipine freeze-drying solid lipid nanoparticle redissolved.
Fig. 1 is the preceding transmission electron microscope photo of Nimodipine freeze-drying solid lipid nanoparticle lyophilizing of the embodiment of the invention 1 preparation, and Fig. 2 is the transmission electron microscope photo after the Nimodipine freeze-drying solid lipid nanoparticle of the embodiment of the invention 1 preparation redissolves.By Fig. 1 and Fig. 2 as can be known, before the lyophilizing of Nimodipine freeze-drying solid lipid nanoparticle and redissolve the equal rounding of back profile, the structure homogeneous.
Two, the particle size distribution of Nimodipine freeze-drying solid lipid nanoparticle is investigated
Be diluted to suitable concentration respectively with sample after sample and Nimodipine freeze-drying solid lipid nanoparticle redissolve before the water for injection of 0.22 μ m microporous filter membrane ultrafiltration is with the Nimodipine solid lipid nanoparticle lyophilizing of the embodiment of the invention 1 and embodiment 7 preparations, put into Nicomp immediately after then
TMIn 380 particle size analyzers, measure particle size distribution, compare with the particle size distribution of solid lipid nanoparticle solution before the lyophilizing, the results are shown in Table 1.
Table 1 particle size distribution measuring result
| Embodiment | PSD (nm) before the lyophilizing | PSD after the redissolution (nm) |
| 1 | 106±45 | 153±47 |
| 7 | 110±39 | 150±54 |
As can be seen from Table 1, the particle size distribution of Nimodipine freeze-drying solid lipid nanoparticle before and after lyophilizing of embodiment 1 and embodiment 7 preparations changes very little, all below 200nm, satisfies the used for intravenous injection requirement.
Three, the zeta potential measurement of Nimodipine freeze-drying solid lipid nanoparticle
Adopt Nicomp
TM380 carry out the mensuration of zeta current potential.After sample is diluted to suitable concentration respectively before the water for injection of 0.22 μ m microporous filter membrane ultrafiltration is with the Nimodipine solid lipid nanoparticle lyophilizing of the embodiment of the invention 1 and embodiment 7 preparations, put into Nicomp immediately
TMIn 380 sample cells, measure the zeta current potential, the results are shown in Table 2.
Table 2zeta potential measurement result
| Embodiment | 1 | 7 |
| Zeta potential (mv) | -14.15 | -13.96 |
As can be seen from Table 2, the zeta current potential of sample is about-14mv before the Nimodipine solid lipid nanoparticle lyophilizing of the present invention preparation, and stability better.
Four, the nimodipine assay of Nimodipine freeze-drying solid lipid nanoparticle and the investigation of envelop rate
Adopt the methanol breakdown of emulsion, with the content of nimodipine in the Nimodipine freeze-drying solid lipid nanoparticle of the HPLC mensuration embodiment of the invention 1 and embodiment 7 preparations, measure envelop rate with the method for external microdialysis, the result is as shown in table 3.
Table 3 Nimodipine solid lipid nanoparticle content and entrapment efficiency determination result
| Embodiment | 1 | 7 |
| Content (%) | 98.45 | 98.32 |
| Envelop rate (%) | 92.56 | 93.14 |
As can be seen from Table 3, the content of the Nimodipine freeze-drying solid lipid nanoparticle of the present invention preparation is all more than 98%, envelop rate all about 93%, steady quality.
Five, the investigation of the long-time stability of Nimodipine freeze-drying solid lipid nanoparticle
The Nimodipine freeze-drying solid lipid nanoparticle of the embodiment of the invention 1 preparation is positioned under room temperature (25 ℃ ± 2 ℃) drying condition stores 3 months, carry out inspection and the mensuration of every physicochemical property respectively at before placing and placement back the 1st, 2, sampling in March, the results are shown in Table 4.
Table 4 Nimodipine freeze-drying solid lipid nanoparticle long-term stable experiment result (25 ℃ ± 2 ℃)
As can be seen from Table 4, placed 3 months under 25 ℃ ± 2 ℃ drying conditions, the outward appearance of Nimodipine freeze-drying solid lipid nanoparticle, residual moisture, pH value, particle diameter and envelop rate all do not have significant change, still meet the intravenous administration requirement.
Six, the release in vitro before and after the lyophilizing of Nimodipine freeze-drying solid lipid nanoparticle
Accurately respectively measure before the lyophilizing and the Nimodipine solid lipid nanoparticle 2mL after redissolving puts in the bag filter, tighten at two ends, places the 50mL conical flask, adds 40mL release medium (pH 7.4 phosphate buffered solution that contain 30% ethanol), gets 3 parts in sample with legal system.Conical flask put in 37 ℃ the water bath chader, 100 times/minute vibrations in 0.5,1,2,3,4,6,8,12,24,36, the 48h 100 μ L that take a sample, and replenish fresh medium with volume, and the medium of taking-up is analyzed with the HPLC method.The results are shown in Table 5.
The release behavior of table 5 Nimodipine freeze-drying solid lipid nanoparticle before and after lyophilizing
As shown in Table 5, all there is tangible burst effect in two preparations, and discharge very fast early stage, and the later stage is tending towards slow.The data curve plotting the results are shown in Figure 3 according to this.Two curves are quite similar, show that bigger change does not take place Nimodipine freeze-drying solid lipid nanoparticle its state before and after lyophilizing.
Seven, the zoopery of Nimodipine freeze-drying solid lipid nanoparticle-rat body giving drugs into nose is for dynamics research
The Wister kind male white rat that to select 12 body weight for use be 200 ± 20g, fasting feedwater before the experiment, rat is divided into two groups at random: matched group and to be checked group, every group 6, mode administration with the right back vena femoralis injection of rat, matched group injection nimotop vial, the to be checked group of Nimodipine freeze-drying solid lipid nanoparticle that injection water for injection redissolves, injected dose is 0.75mgkg
-1, respectively at 5min after the administration, 10min, 20min, 30min, 45min, 1h, 2h, 4h, the 6h eye socket is got blood 0.5mL, places the 1.5mL conical centrifuge tube of heparinization in advance, the centrifugal 10min of 4000rpm, separated plasma ,-70 ℃ of preservations, to be measured.
The plasma sample 100 μ L that preserve are placed the 7mL centrifuge tube, add 20 μ L inner mark solution (4 μ gmL
-1Nitrendipine solution), 20 μ L methanol and 20 μ L NaOH (0.1M), vortex 30 seconds, mixing; Add 3mL ether-normal hexane (volume ratio 1: 1), vortex 10min; Then in the centrifugal 10min of 4000rpm, get supernatant 2mL and place the 5mL centrifuge tube, with the vacuum evaporation desolventizing under 40 ℃ of conditions of the centrifugal concentrate drying instrument of U.S. LABCONCO company, residue adds 1mL methanol and redissolves, vortex 5min mixes, the centrifugal 10min of refrigerated centrifuger 12000rpm gets supernatant 5 μ L sample introduction UPLC-ESI-MS/MS and analyzes, rat each the time blood drug level the results are shown in Table 6 and table 7.
The present invention of table 6 single dose vena femoralis injection
Behind the Nimodipine freeze-drying solid lipid nanoparticle rat each the time blood drug level
Behind the table 7 single dose vena femoralis injection nimotop vial rat each the time blood drug level
Draw matched group and to be checked group of average blood drug level of rat and time relation curve, the results are shown in Figure 4.As can be seen from the figure, behind intravenous injection Nimodipime nanometer solid lipid nanoparticle and the nimodipine solution-type injection, two kinds of preparation pharmacokinetics behaviors in the rat body are similar substantially, but because the blood drug level of initial stage solid lipid nanoparticle group is higher than the solution group, cause the blood drug level of nanoparticle in the whole observation process all the time greater than the solution group.This may be owing to medicine after the administration of nimodipine solution is distributed to rapidly its initial plasma drug level to be reduced rapidly.And for the nanoparticle group, the nimodipine medicament more than 90% is present in phospholipid bilayer and surface thereof.Therefore after the administration, medicine needs the regular hour, is diffused in the blood plasma, and then is distributed in the tissue, therefore causes the initial blood drug level of Nimodipine nanometer granule group to be higher than its solution.Simultaneously by the compartment model parameter as can be known, two preparations all meet three compartment models, the pharmacokinetics behavior basically identical of its medicine.Thereby cause in whole metabolic process, the blood drug level of nanoparticle group is higher than the solution group.
Using DAS2.0 statistical computation software (mathematics pharmacology Professional Committee of Chinese Pharmacological Society) pharmacokinetics program handles the blood drug level data of Nimodipine freeze-drying solid lipid nanoparticle and nimotop vial.Judge that according to AIC value and degree of fitting both compartment models belong to, result of calculation shows that the blood drug level data of Nimodipine freeze-drying solid lipid nanoparticle and nimotop vial all meet three compartment models.
The evaluation of non-compartment model pharmacokinetic parameter and bioequivalence: adopt statistical moment that the blood drug level data are calculated, the physiological disposition of analyzing medicine with statistical moment belongs to a kind of analytical method of non-compartment, so it does not need medicine is set special compartment.The pharmacokinetics program of DAS2.0 statistical computation software is used in this experiment, according to blood drug level-described physiological disposition of time measured data, calculate the statistical moment pharmacokinetic parameter of Nimodipine freeze-drying solid lipid nanoparticle and nimotop vial, the results are shown in Table 8.
The non-compartment model match of table 8 nimodipine of the present invention
Every pharmacokinetic parameters of lyophilized solid lipid nanoparticle and reference solution agent
| Parameter | Unit | The Nimodipine freeze-drying solid lipid nanoparticle | Nimotop vial |
| AUC(0-t) | μg/L*h | 469.953±67.75 | 343.677±82.791 |
| AUC(0-∞) | μg/L*h | 484.489±78.058 | 345.956±84.314 |
| Maximum plasma concentration | μg/L | 804.433±117.519 | 600.6±133.676 |
| Peak time of drug | h | 0.083±0 | 0.083±0 |
| Half-life | h | 0.797±0.187 | 0.545±0.108 |
Use the bioequivalence program of DAS2.0 statistical computation software, the pharmacokinetic parameters of his-and-hers watches 8 is estimated.Employing is to number conversion, and to AUC, maximum plasma concentration has carried out two-way one-side t check, and the result shows two preparation equivalences.
In sum, Nimodipine freeze-drying solid lipid nanoparticle of the present invention, its drug loading can reach 0.2mg/mL, it is in good condition to redissolve the back, and its physicochemical property meets the used for intravenous injection requirement, has efficient, low toxicity, characteristics such as stable, can improve patient's compliance, be suitable for clinical practice.Nimodipine freeze-drying solid lipid nanoparticle of the present invention and nimotop vial equivalence have avoided in the injection ethanol to the zest of blood vessel, are efficient, low toxicity, stable nimodipine novel form.
The above; it only is preferred embodiment of the present invention; be not that the present invention is imposed any restrictions, every any simple modification, change and equivalent structure of above embodiment being done according to the technology of the present invention essence changes, and all still belongs in the protection domain of technical solution of the present invention.
Claims (9)
1. a Nimodipine freeze-drying solid lipid nanoparticle is characterized in that, mixes the back lyophilizing with freeze drying protectant by solid lipid nanoparticle solution and makes, and adds 20g～40g freeze drying protectant in every 100mL solid lipid nanoparticle solution; The described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 2mg～20mg, and phosphatidase 10 .5g～4g, cholesterol sodium sulfate salt 0g～0.2g, propylene glycol block polyether 0.02g～0.4g, surplus is phosphate buffered solution; Described freeze drying protectant is one or more in sucrose, glucose, trehalose, maltose and the mannitol;
The preparation method of described Nimodipine freeze-drying solid lipid nanoparticle may further comprise the steps:
Step 1, take by weighing nimodipine, phospholipid and cholesterol sodium sulfate salt respectively, nimodipine, phospholipid and the cholesterol sodium sulfate salt that takes by weighing mixed back heating for dissolving under magnetic agitation, obtain the homogeneous oil phase;
Step 2, to take by weighing propylene glycol block polyether and the propylene glycol block polyether that takes by weighing is dissolved in pH value be in 6.5～7.5 the phosphate buffered solution, obtains water;
Step 3, water described in the step 2 is heated to identical with the temperature of oil phase described in the step 1, the water after will heating under stirring condition then splashes into described in the step 1 in the oil phase, disperses to obtain colostrum;
Step 4, be 6.5～7.5 phosphate buffered solution standardize solution with the pH value of colostrum described in the step 3, ultra-sonic dispersion then, the ultrafiltration sterilization of cooling back obtains solid lipid nanoparticle solution;
Step 5, take by weighing freeze drying protectant and the freeze drying protectant that takes by weighing is dissolved in the solution of solid lipid nanoparticle described in the step 4, packing, lyophilizing obtains the Nimodipine freeze-drying solid lipid nanoparticle.
2. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 1, it is characterized in that, the described solid lipid nanoparticle solution of 100mL is made by following raw material: nimodipine 20mg, phosphatidase 12 g, cholesterol sodium sulfate salt 0.1g, propylene glycol block polyether 0.2g, surplus is phosphate buffered solution.
3. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 1 and 2 is characterized in that, described phospholipid is injection stage Ovum Gallus domesticus Flavus lecithin PL-100M; Described propylene glycol block polyether is propylene glycol block polyether F-68.
4. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 1 and 2 is characterized in that, described freeze drying protectant is mannitol and trehalose, and the mass ratio of mannitol and trehalose is 1: 2.
5. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 4 is characterized in that, adds mannitol and the trehalose of 30g in every 100mL solid lipid nanoparticle solution.
6. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 1 is characterized in that, the temperature that heats described in the step 1 is 60 ℃.
7. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 1 is characterized in that, stir speed (S.S.) described in the step 3 is 500rpm.
8. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 1 is characterized in that, ultrasonic power is 750W described in the step 4, and ultrasonic time is 10min.
9. a kind of Nimodipine freeze-drying solid lipid nanoparticle according to claim 8 is characterized in that, described ultrasonic employing is ultrasonic power at interval, is specially: the every processing of ultrasound wave 3s, intermittently 1s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210083247.5A CN102552156B (en) | 2012-03-27 | 2012-03-27 | Nimodipine freeze-dried solid lipid nanoparticle and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210083247.5A CN102552156B (en) | 2012-03-27 | 2012-03-27 | Nimodipine freeze-dried solid lipid nanoparticle and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552156A CN102552156A (en) | 2012-07-11 |
| CN102552156B true CN102552156B (en) | 2013-08-21 |
Family
ID=46399627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210083247.5A Active CN102552156B (en) | 2012-03-27 | 2012-03-27 | Nimodipine freeze-dried solid lipid nanoparticle and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552156B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705514B (en) * | 2013-12-27 | 2015-12-30 | 李宏 | A kind of composition and method of making the same containing nimodipine and application |
| CN105662921B (en) * | 2015-12-25 | 2018-07-17 | 吉林农业大学 | A kind of preparation method of freeze-drying oil body |
| CN107019682B (en) * | 2017-04-13 | 2019-09-03 | 中国药科大学 | A kind of Nimodipine lipid nanoparticle and its preparation process |
| CN114617903A (en) * | 2022-03-15 | 2022-06-14 | 中国人民解放军总医院第一医学中心 | Composition for plasma freeze-drying and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418626A (en) * | 2002-12-13 | 2003-05-21 | 沈阳药科大学 | Nimodipine lipid nano particle compositions, and its prepn. method |
| CN1554340A (en) * | 2003-12-23 | 2004-12-15 | 中国药科大学 | Nimoldipine new nano liposome, its precursor freeze dryed matter and its preparing method |
| CN1903173A (en) * | 2006-07-12 | 2007-01-31 | 张文芳 | Nimodipine nanometer granule and its prepn. method |
| CN101045054A (en) * | 2006-03-29 | 2007-10-03 | 上海医药工业研究院 | Nimodipime nanometer suspension freeze-dried composition, its preparing method and use |
| CN101485632A (en) * | 2009-02-11 | 2009-07-22 | 西安德天药业股份有限公司 | Nimodipine lipid microsphere injection and preparation method thereof |
-
2012
- 2012-03-27 CN CN201210083247.5A patent/CN102552156B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418626A (en) * | 2002-12-13 | 2003-05-21 | 沈阳药科大学 | Nimodipine lipid nano particle compositions, and its prepn. method |
| CN1554340A (en) * | 2003-12-23 | 2004-12-15 | 中国药科大学 | Nimoldipine new nano liposome, its precursor freeze dryed matter and its preparing method |
| CN101045054A (en) * | 2006-03-29 | 2007-10-03 | 上海医药工业研究院 | Nimodipime nanometer suspension freeze-dried composition, its preparing method and use |
| CN1903173A (en) * | 2006-07-12 | 2007-01-31 | 张文芳 | Nimodipine nanometer granule and its prepn. method |
| CN101485632A (en) * | 2009-02-11 | 2009-07-22 | 西安德天药业股份有限公司 | Nimodipine lipid microsphere injection and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| Injectable nimodipine-loaded nanoliposomes: Preparation, lyophilization and characteristics;T.Guan,et al;《International Journal of Pharmaceutics》;20110315;第410卷;第180－187页 * |
| T.Guan,et al.Injectable nimodipine-loaded nanoliposomes: Preparation, lyophilization and characteristics.《International Journal of Pharmaceutics》.2011,第410卷第180－187页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552156A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200369714A1 (en) | A Novel Blank Liposome with Ginsenoside Rg3 or its Analog as Membrane Materials and Preparations and Uses Thereof | |
| Gao et al. | Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin | |
| CN101474155B (en) | Lung-targeted medicine carrying precursor liposome for injection and method of use thereof | |
| CN101909614B (en) | Nanodispersion | |
| CN101653414B (en) | Long-circulating solid lipid docetaxel nanoparticles and preparation method thereof | |
| CN102552156B (en) | Nimodipine freeze-dried solid lipid nanoparticle and preparation method thereof | |
| Sou et al. | Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo | |
| WO2011066684A1 (en) | Liposome of irinotecan or its hydrochloride and preparation method thereof | |
| JPH08268893A (en) | Medicinal composition for intravenous administration of staurosporin derivative | |
| CN104936620A (en) | Nanoparticle formulations with enhanced mucosal penetration | |
| CN100367953C (en) | Quercetin solid liposome nano particle preparation and its preparing method | |
| Xin et al. | PLGA nanoparticles introduction into mitoxantrone-loaded ultrasound-responsive liposomes: In vitro and in vivo investigations | |
| CN104173290A (en) | Solid lipid nanoparticle or liposome and preparation method thereof | |
| CN103720658B (en) | Heparin modified Evacet preparation and preparation method thereof | |
| CN106267248A (en) | A kind of lipid ultrasonic microvesicle carrying modified with folic acid mesoporous silicon dioxide nano particle and preparation method thereof | |
| Su et al. | Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in a lipid emulsion | |
| CN102366411B (en) | Dexamethasone palmitate acid liposome injection | |
| CN109568297A (en) | A kind of dihydromyricetin solid lipid nano granule and preparation method | |
| CN102552134B (en) | Fat emulsion containing vitamin K1 | |
| CN104997759B (en) | A kind of total toadpoison lactone solid lipid nano granule drug delivery system of injection and preparation method thereof | |
| CN104324007B (en) | Preparation technology and application of natural recombinant nanostructured lipid carrier | |
| CN103735504B (en) | A kind of irinotecan nanometer fat bundle preparation and preparation method thereof | |
| CN103989624B (en) | A kind of irinotecan hydrochloride composition and preparation method thereof | |
| CN105919935B (en) | Sorafenib medicine lipid nano suspension and preparation method thereof | |
| Yin et al. | Preparation and evaluation of etoposide-loaded lipid-based nanosuspensions for high-dose treatment of lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 710119 No. 9, innovation road, new industrial park, Xi'an hi tech Industrial Development Zone, Shaanxi Patentee after: Xi'an Yuanda Detian pharmaceutical Limited by Share Ltd Address before: 710119 No. 9, Chuangxin Road, new industrial park, hi tech Zone, Shaanxi, Xi'an Patentee before: Xi'an Detian Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20220429 Address after: 710119 No. 9, Chuangxin Road, Zhangba Street office new industrial park, high tech Zone, Xi'an, Shaanxi Province Patentee after: Xi'an Yuanda Kechuang Pharmaceutical Technology Co.,Ltd. Address before: No.9, Chuangxin Road, new industrial park, Xi'an hi tech Industrial Development Zone, Shaanxi 710119 Patentee before: XI'AN GRAND DETEN PHARMACEUTICAL CO.,LTD. |
|
| TR01 | Transfer of patent right |